CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

MIVI Neuroscience

MIVI Neuroscience, (MIVI) is an innovative medical device company that aims to achieve life-giving results for an increasing number of patients experiencing acute ischemic stroke (AIS).

Xytex Sperm Bank

Xytex Sperm Bank is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

INNOVATIVE MEDICAL MANUFACTURING

INNOVATIVE MEDICAL MANUFACTURING is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shockwave Medical

Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotrispy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. In peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, IVL demonstrated safety and consistent procedure success with low procedural complications. The technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatments. And because it is built on a traditional balloon catheter platform, it integrates seamlessly with clinicians` existing workflow.

JEOL

JEOL USA, Inc. is a wholly owned subsidiary of JEOL, Ltd. of Akishima, Japan.JEOL USA, Inc. was incorporated in the United States in 1962, and moved to present corporate offices at 11 Dearborn Road in Peabody, Massachusetts, in August 1979. The primary